Sanofi-Aventis Germany GmbH
Frankfurt/Main (ots)
“It wasn’t just an itch, it was really painful. I wasn’t able to do anything anymore,” says Simone, describing her illness. She suffers from prurigo nodularis, also known as chronic nodular prurigo, an inflammatory skin disease that poses many challenges to those affected. Because prurigo nodularis is characterized by extreme itching and entails restrictions in all areas of life. For many people, the disease is unknown, because prurigo nodularis is rather rare. Information on this topic has recently been made available on the new website prurigo-nodularis.info. The aim of the site is to provide information about the disease and to provide assistance.
This is what the new website offers
Those affected and those interested can find out everything that is important here: from the symptoms to the causes and current treatment options. There is also the possibility for those affected to self test to record their illness situation and thus to obtain an assessment of how well their illness is currently controlled. Also addresses from experts for chronic itch are available on the site. The website also provides information on various offers of help. Because the many limitations that the disease brings with it can affect self-esteem, self-awareness and relationships with other people. The exchange with people who are in a similar situation can therefore be helpful for those affected.
Understanding nodular pruritus
The rare inflammatory skin disease is accompanied by extremely itchy, red nodules, which are usually symmetrically distributed and can vary in size from 3 mm to 2 cm.[1] Those affected suffer in particular from pronounced itching.[2,3] This is accompanied by intensive and repeated scratching of the affected skin areas. The result: damage to the skin.[3,4] The disease can occur in all age groups, in all skin types and all ethnic groups. However, women over the age of 50 and people of color seem to be more affected.[5] In Germany, about 100 out of 100,000 people suffer from the disease.[6]
For more information on prurigo nodularis visit the new Website.
Credentials:
[1] Zeidler C et al. Acta Derm Venereol 2018; 98(2): 173-179
[2] Iking A et al. J Eur Acad Dermatol Venereol 2013; 27(5): 550-557
[3] Pereira MP et al. J Eur Acad Dermatol Venereol 2020; 34:2373-2383
[4] Pereira MP et al. J Eur Acad Dermatol Venereol 2018; 32(7): 1059-1065
[5] Williams KA et al. Exp Rev Clin Pharmacol 2021; 14(1); 67-77
[6] Stander S et al. Act Derm Venereol 2020; 100: adv00309
About Sanofi
We are an innovative global healthcare company with a single purpose: to explore the wonders of science to improve people’s lives. Our team works in more than 100 countries to change the practice of medicine and make the impossible possible. We provide life-saving vaccines and treatment options that have the potential to improve lives to millions of people around the world. In doing so, we place sustainability and social responsibility at the center of everything we do.
Sanofi is listed on the EURONEXT: SAN and NASDAQ: SNY stock exchanges.
MAT-DE-2300873-1.0-03/2023
Press contact:
Telse Friccius
Tel.: + 49 (0) 69 305-23941
[email protected]
Original content from: Sanofi-Aventis Deutschland GmbH, transmitted by news aktuell